The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed ? the first clinical trial of a cancer vaccine using novel ROP technology.
NEWS ROOM
Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200
Administrator2023-03-29view:1721
돌아가기
